FDA approves DaunoXome as first-line therapy for Kaposi's sarcoma. Food and Drug Administration.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003630:Daunorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D017277:Drug Approval; D004337:Drug Carriers; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008081:Liposomes; D011788:Quality of Life; D012514:Sarcoma, Kaposi / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D004337:Drug Carriers; D008081:Liposomes; D003630:Daunorubicin